Talen-based gene correction
US10172880B2 · kind B2 · utility
2Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2016 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Feb 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/86
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.